Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Mult Scler · 2015 · PMC4361497 · PMID 25344374

Europe PMC DOI

hedged sentence

0.2200

closest p · 4.4× alpha

0.2200

boldest claim

The sentences

did not reach statistical significancep = 0.22not close (p > 0.1)

7 , 9 There was a 30% reduction in six-month SAD that did not reach statistical significance (alemtuzumab, 8% vs SC IFNβ-1a, 11%; p = 0.22), with the mean EDSS score change from baseline being −0.14 in both the alemtuzumab and the SC IFNβ-1a arms ( p = 0.97).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.